Bone changes and curative effect of infliximab in patients with ankylosing spondylitis

Linying Li¹, Bin Chen², Haiyan Zhao³, Gengshen Wang⁴

¹Anesthesia Operating Room, Wuwei People’s Hospital, Wuwei, P.R. China; ²Infections Department, Wuwei People’s Hospital, Wuwei, P.R. China; ³Department of Orthopedics, The First Hospital of Lanzhou University, Lanzhou, P.R. China; ⁴Department of Orthopedics, Wuwei People’s Hospital, Wuwei, P.R. China

Abstract

Objectives: To study the bone changes and curative effect of infliximab in patients with ankylosing spondylitis (AS).

Methods: AS patients diagnosed and treated in Wuwei People’s Hospital from January 2017 to March 2018 were collected as the study subjects of this study, and the patients were divided into INF group (n=40) and MTX group (n=40) according to the random number table. The expression levels of TNF-α and IL-33 before and after treatment were detected by enzyme-linked immunosorbent assay (ELISA), and bone changes before and after treatment were compared between the two groups. The ROC curves of TNF-α and IL-33 for efficacy prediction of AS were drawn and analyzed.

Results: After treatment, the expression levels of serum TNF-α and IL-33 in patients in INF group were significantly lower than those in MTX group (P<0.001), and the improvement of bone erosion and tendon thickening in INF group was markedly higher than that in MTX group (P<0.001). The receiver operating characteristic (ROC) curve revealed that the area under the curve (AUC) of TNF-α for predicting efficacy was 0.939, and that of IL-33 was 0.853.

Conclusions: Infliximab can significantly improve the bone status and has a positive effect in patients with AS, and TNF-α and IL-33 are expected to be used as efficacy predictors of AS.

Keywords: Ankylosing Spondylitis, Efficacy Prediction, IL-33, Infliximab

Introduction

Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disease that is characterized by new bone formation in the axial bones, often resulting in progressive, irreversible structural damage and disability¹,². The onset of AS commonly occurs in people younger than 45³, and the prevalence is between 0.1% and 1.4% globally⁴. It is a common rheumatic disease in China, and more than 90% of Chinese patients are predominantly HLA-B*2704 subtype and HLA-B27 positive, among which the incidence of the latter accounts for 4% to 8% in the general Chinese population⁵. In a study in Taiwan, the incidence of male AS was lower in people under 19 years old, peaked rapidly between 20 and 24 years old, and then gradually declined⁶. AS will severely affect the spinal range of motion and physical function, leading to a low quality of life and posing a direct threat to the physical and mental health of young people. Therefore, the development of safe and effective treatments is essential.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay of treatment for AS. Among them, indomethacin combined with methotrexate is commonly used for the treatment of AS; however clinical observation over the recent years has revealed that its efficacy is moderate, and it has no significant effect on improving the prognosis⁷. At the same time, conventional treatment will slow down the radiological progress. Tumor necrosis factor (TNF-α) inhibitors are found to be able to make up the shortage of NSAIDs and improve patients’ quality of life⁸. TNF-α is a cytokine produced by activated macrophages that can inhibit osteoblasts and stimulate osteoclasts, which can directly kill tumor cells.
without significant toxicity to normal cells. TNF-α and IL-33 are overexpressed in patients with AS and are involved in the development of the disease, which may regulate the immune or inflammatory process of AS\(^1,10\). Infliximab, as one of TNF-α inhibitors, can effectively reduce the level of TNF-α. Studies have confirmed its safety and effectiveness in long-term treatment\(^11\), as well as its significant effect on improving bone density\(^2\). As the commonly used drugs in the clinical treatment of AS in recent years, TNF-α inhibitors have shown considerable clinical efficacy, but studies on the predictive value of TNF-α and IL-33 in clinical efficacy are still scarce.

In this study, conventional drugs and infliximab were applied to treat AS patients to study their effects on bone, clinical efficacy as well as the predictive value in AS.

**Methods and materials**

**Clinical data collection**

Patients with AS who were diagnosed and treated in Wuwei People’s Hospital from January 2017 to March 2018 were collected and randomly divided into two groups: INF group (n=40) and MTX group (n=40). There were 29 males and 11 females in the INF group, with an average age of 29.1±7.6 years, while in MTX group, there were 28 males and 12 females with an average age of 28.8±8.1 years. The study was approved by the Medical Ethics Committee of Wuwei People’s Hospital.

**Inclusion and exclusion criteria**

AS patients diagnosed and treated in our hospital, and the diagnostic criteria were referred to the 1984 modified New York Criteria of Evaluation of Diagnostic Criteria for Ankylosing Spondylitis\(^3\). The inclusion criteria were the following: Low back pain and stiffness for more than 3 months, which would improve only during exercise, but not at rest; Limited movement of lumbar saqittal and coronal; Thoracic activity lower than healthy people of similar age and gender; Bilateral sacral arthritis reached or exceeded grade II or unilateral sacral arthritis grade III-IV.

The exclusion criteria were: Patients with high methotrexate allergy, allergy to mouse protein, renal insufficiency, active gastric and duodenal ulcers, moderate and severe heart failure, infection, low blood volume, coagulation, or mental disorder.

**Treatment plan**

Patients in the INF group received an intravenous injection of infliximab (Cilag AG, Switzerland, registration number: S20171001). Patients were given at the first dose of 5 mg/k, followed by the same dose at 2 and 6 weeks after the first administration and every 6 weeks after that. While patients in the MTX group were treated with conventional drug treatment: Indomethacin sustained-release capsules (Minghe Pharmaceutical Co., Ltd., Hubei, China, State Drugs Administration License No.: H20030063) was orally administrated at 75 mg/time and 1d/time. Also, another oral administration of methotrexate tablets (Sine Pharmaceutical Laboratories Co., Ltd., Shanghai, China, State Drugs Administration License No.: H31020644) was taken at 5 mg/time, once daily. Patients in both groups were treated continuously for 30 weeks.

**Sample collection and testing**

On the morning of the second day after admission and 30-week treatment, 3 ml of blood was taken from the veins on an empty stomach from each enrolled AS patient, and meanwhile, the same amount of blood samples were drawn from the control group. All the blood samples were left at room temperature for 30 min and centrifuged at 3000 rpm/min for 10 min. Then the supernatant was collected and stored in the refrigerator at -80°C for centralized detection.

ELISA was adopted to measure the serum expression levels of TNF-α (human TNF alpha ELISA kit, Abcam (Shanghai) Trading Co., Ltd., ab181421) and IL-33 (human The expression of IL-33 ELISA kit, Abcam (Shanghai) Trading Co., Ltd., ab223865). Blank wells, standard wells, and sample wells to be tested were set. Blank wells were added with 0 concentration, while standard wells with standard samples, and sample wells with the sample to be tested. In addition to the sample wells, all other wells were added with sample dilutions and horseradish peroxidase (HRP)-labeled antibodies. Then, unbound biotinylated antibodies were removed thorough washing, and HRP-labeled avidin was added. After washing again, TMB substrate was added for color development. TMB turned blue under catalysis and yellow under the action of acid. Finally, the absorbance (OD value) was measured with a microplate reader at a wavelength of 450 nm, and the corresponding concentration was converted from the standard curve.

**Outcome measures**

Main outcome measures: Bone changes and the expression levels of TNF-α and IL-33 before and after treatment in the two groups were recorded and compared. In addition, Physician global assessment (PGA) score was applied to evaluate the clinical efficacy of the two groups after 30 weeks of treatment (curative effect evaluation standard are shown in Table 1). Serum TNF-α and IL-33 expressions of the two groups of patients before and after treatment were observed. What’s more, according to post-treatment conditions, patients who

---

**Table 1. Evaluation criteria for clinical efficacy.**

| Efficacy level | Evaluation criteria |
|---------------|---------------------|
| Basically cured | PGA score ≥9 |
| PGA score ≥9   | PGA score: 6-9 |
| Improved       | PGA score: 2.5-5.9 |
| Ineffective    | PGA score < 2.5 |
were basically cured and showed markedly effective were divided into good curative effect group, while those who were improved and ineffective were divided into the poor curative effect group. The expression levels of TNF-α and IL-33 in the two groups before treatment were observed, and ROC curve was drawn.

Secondary outcome measures: Changes in clinical outcome measures before and after treatment in the two groups were observed (Table 1).

### Table 2. Baseline data of patients.

| Factors                  | INF group (n=40) | MTX group (n=40) | t/χ² value | P value |
|--------------------------|------------------|------------------|------------|---------|
| Age (years)              | 29.1±7.6         | 28.8±8.1         | 0.171      | 0.865   |
| Gender                   |                  |                  |            |         |
| Male                     | 29 (72.50)       | 28 (70.00)       | 0.061      | 0.804   |
| Female                   | 11 (27.50)       | 12 (30.00)       |            |         |
| BMI (kg/m²)              | 22.4±1.5         | 22.8±1.3         | 1.275      | 0.206   |
| Smoking history          |                  |                  |            |         |
| Yes                      | 12 (30.00)       | 13 (32.50)       | 0.058      | 0.809   |
| No                       | 28 (70.00)       | 27 (67.50)       |            |         |
| Family medical history   |                  |                  |            |         |
| Yes                      | 5 (12.50)        | 6 (15.00)        | 0.105      | 0.745   |
| No                       | 35 (87.50)       | 34 (85.00)       |            |         |
| Residence                |                  |                  |            |         |
| Rural                    | 22 (55.00)       | 24 (60.00)       | 0.205      | 0.651   |
| Urban                    | 18 (45.00)       | 16 (40.00)       |            |         |
| CRP (mg/L)               | 11.92±7.63       | 12.16±7.42       | 0.143      | 0.887   |
| ESR (mm)                 | 21.34±8.27       | 20.87±9.12       | 0.241      | 0.810   |

### Figure 1. Changes in serum TNF-α and IL-33 expression levels before and after treatment in the two groups of patients. A) Changes in serum TNF-α expression level before and after treatment in the two groups. There was no significant difference in serum TNF-α level between INF group (28.427±7.138) and MTX group (27.892±6.427) before treatment. While it decreased significantly after treatment in the two groups, and the serum TNF-α level in INF group (12.146±5.752) was significantly lower than that in MTX group (18.248±13.426). B) Changes in serum IL-33 expression level before and after treatment in the two groups. No significant difference was found in serum IL-33 level between INF group (261.152±28.443) and MTX group (256.763±26.976) before treatment. While the level of serum IL-33 dropped notably in the two groups after treatment, and the serum IL-33 level in INF group (121.274±13.426) was remarkably lower than that in MTX group (137.582±16.223) (P<0.001). *** indicated P<0.001.

### Statistical analysis

The collected data were statistical analyzed by SPSS20.0 (Cabit Information Technology Co., Ltd., Shanghai, China), and the required images were plotted using Prism 7 (Softhead Technology Co., Ltd., Shenzhen, China). The counting data were expressed in the form of percentage (%), and compared using Chi-square (expressed as X²). The measurement data were expressed as (Mean±SD), and the comparison between...
the two groups of normal distribution data was performed using the independent sample t test, which was expressed as P<0.05 indicated that there was a statistical difference between the two groups.

Results

Comparison of clinical data between the two groups

There were no significant differences in age, gender, BMI, smoking history, family history, place of residence or other laboratory indicators in the two groups of patients (P>0.05) (Table 2).

Changes in serum TNF-α and IL-33 expression levels before and after treatment in the two groups

The comparison of serum TNF-α and IL-33 expression levels of patients in the two groups before and after treatment showed no significant difference in serum TNF-α (28.42±7.138) (27.89±6.427) and IL-33 (261.15±28.443) (256.76±26.976) levels between INF group and MTX group before treatment. After treatment, the expression levels of serum TNF-α (12.146±5.752) and IL-33 (121.27±13.426) (137.56±16.223) decreased significantly in both groups (P<0.001), and the serum TNF-α and IL-33 in patients in INF group were substantially lower than those in MTX group (P<0.001) (Figure 1).

Table 3. Bone changes in the two groups before and after treatment.

| Indexes                  | INF Group (n=40) | MTX Group (n=40) | X² value | P value |
|--------------------------|------------------|------------------|----------|---------|
| Bone erosion             |                  |                  |          |         |
| Before treatment         | 31 (77.50)       | 33 (82.50)       | 0.313    | 0.576   |
| After treatment          | 8 (20.00)        | 17 (42.50)       | 4.713    | 0.030   |
| Osteophyte               |                  |                  |          |         |
| Before treatment         | 2(5.00)          | 3 (7.50)         | 0.213    | 0.644   |
| After treatment          | 1 (2.50)         | 2 (5.00)         | 0.346    | 0.556   |
| Tendon thickening        |                  |                  |          |         |
| Before treatment         | 17 (42.50)       | 18 (45.00)       | 0.503    | 0.478   |
| After treatment          | 4 (10.00)        | 10 (25.00)       | 4.021    | 0.045   |
| Tendon calcification     |                  |                  |          |         |
| Before treatment         | 2 (5.00)         | 1 (2.50)         | 0.346    | 0.346   |
| After treatment          | 2 (5.00)         | 1 (2.50)         | 0.346    | 0.346   |

Table 4. Changes in clinical efficacy indexes before and after treatment in the two groups.

| Indexes                  | INF group (n=40) | MTX group (n=40) | T value | P value |
|--------------------------|------------------|------------------|---------|---------|
| Morning stiffness time (min) | 74±32           | 76±29            | 0.248   | 0.805   |
| Before treatment         | 13±8             | 18±7             | 2.975   | 0.004   |
| After treatment          | 4.56±2.64        | 4.62±2.49        | 0.105   | 0.015   |
| BASFI                    | 5.86±1.64        | 5.78±1.81        | 2.99±1.34 | 3.106  |
| Before treatment         | 2.03±1.22        | 3.14±1.42        | 1.98±1.56 | 3.066  |
| After treatment          | 4.22±1.63        | 4.17±1.78        | 5.86±1.64 | 4.021  |
| BASDAI                   | 8.03±1.12        | 7.11±1.34        | 2.03±1.22 | 3.300  |
| Before treatment         | 4.22±1.63        | 4.17±1.78        | 5.86±1.64 | 4.021  |
| After treatment          | 8.03±1.12        | 7.11±1.34        | 2.03±1.22 | 3.300  |
| PGA                      |                  |                  | 0.131   | 0.001   |

Bone changes in the two groups before and after treatment

Of all the 40 patients in the INF group, 31 cases of bone erosion, 2 cases of osteophyte, 17 cases of tendon thickening, and 2 cases of tendon calcification were found before treatment. While there were 33 cases of bone erosion, 3 cases of osteophyte, 18 cases of tendon thickening, and 1 case of tendon calcification in the MTX group before treatment. There was no significant difference in the number of cases of bone lesions between the two groups before treatment (P>0.05). After treatment, there were 8 cases of bone erosion, 1 case of osteophyte, 4 cases of tendon thickening and 2 cases of tendon calcification in the INF group, while in MTX group, there were 17 cases of bone erosion, 2 cases of osteophyte, 10 cases of tendon thickening and 1 case of tendon calcification. The results, as mentioned above, indicated that the degree of bone improvement in the INF group was better than that in the MTX group (P<0.001) (Table 3).

Changes in clinical efficacy indexes before and after treatment in the two groups

There was no significant difference in the indexes of morning stiffness time (74±32) (76±29), Bath Ankylosing Spondylitis Functional Index (BASFI) (4.56±2.64) (4.62±2.49), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (5.86±1.64) (5.78±1.81), PGA
L. Li et al.: Bone changes and curative effect of infliximab in patients with ankylosing spondylitis

Table 5. Comparison of clinical efficacy between the two groups.

| Groups         | Basically cured | Markedly effective | Improved   | Ineffective | Total effective rate |
|----------------|-----------------|--------------------|------------|-------------|----------------------|
| INF group (n=40) | 15.00 (37.50)   | 14.00 (35.00)      | 9.00 (22.50) | 2.00 (5.00) | 5 (95.00)            |
| MTX group (n=40)  | 9.00 (22.50)    | 13.00 (32.50)      | 12.00 (30.00) | 6.00 (15.00) | 35 (85.00)           |
| T value         |                 |                    |            |             | 0.018                |
| P value         |                 |                    |            |             | 5.556                |

Figure 2. Expression of TNF-α and IL-33 in serum of patients with good and poor curative effect before treatment. A) The serum TNF-α level in the good curative effect group (25.16±3.583) before treatment was notably lower than that of the poor curative effect group (31.23±3.274). B) The serum IL-33 level in the good curative effect group (242.74±23.582) was significantly lower than that of the poor curative effect group (276.34±22.465) (P<0.001).

Predictive value of TNF-α and IL-33 in patients with AS

The patients in the INF group were grouped according to their clinical efficacy after treatment. The patients who were cured and those with marked effectiveness were divided into good curative effect group (n=51), and the improved and ineffective patients were divided into poor curative effect group (n=29). It was observed that the expression levels of serum TNF-α and IL-33 in the good curative effect group were markedly lower than those of the poor curative effect group, showing a significant difference (P<0.001), as shown in Figure 2. Subsequently, ROC curves were drawn based on the expression levels of TNF-α and IL-33 before treatment in the two groups. The results showed that the AUC of TNF-α in predicting efficacy was 0.939, 95CI%: 0.886-0.992, sensitivity: 93.33%, specificity: 88.00, and Youden index: 81.33%. While the AUC of IL-33 in predicting efficacy was 0.853, 95CI%: 0.754-0.952, sensitivity: 93.33%, specificity: 88.00%, and Youden index: 81.33%, as shown in Figure 3.
Discussion

AS has common clinical manifestations and genetic susceptibility\(^4\), with higher mortality and disability. The pathogenesis of AS remains unclear. The development of ossification in early AS patients is related to inflammation\(^5\), as reported by Walter et al\(^6\), inflammation promoted osteophyte formation. Studies have shown that the inflammatory factor IL-33 is highly expressed in AS patients, which can improve the role of TNF-α and participate in the development of AS\(^7\). There is also evidence that TNF-α inhibitors can lead to bone renewal and balance, which is beneficial to bone formation\(^8\). As a commonly used TNF-α inhibitor in clinical practice, INF is comparable to methotrexate in terms of serious adverse events. At the same time, with better efficacy, so infliximab is more advantageous in treatment\(^9\). In this study, conventional drugs and infliximab were used to treat patients with AS, and their effects on TNF-α and IL-33 expression levels, bone changes and clinical efficacy were studied.

In the present study, the included AS patients were divided into INF group and MTX group according to different treatment methods. By detecting the changes of serum TNF-α and IL-33 expression levels before and after treatment, it was found that there was no significant difference in them between the two groups before treatment. After treatment, the serum TNF-α and IL-33 expression levels decreased significantly in both groups, and the expression levels of TNF-α and IL-33 in serum of patients in INF group were markedly lower than those of patients in MTX group, indicating that TNF-α and IL-33 may be implicated in the progression of AS, suggesting that the two may be used as predictors of curative effect of this disease. It also shows that infliximab could significantly reduce inflammation and improve the condition compared with traditional drugs. In the study of Gong et al\(^20\), IL-33 and IL-33 mRNAs were significantly elevated in patients with AS, suggesting that they played an important role in the development of AS, which was basically consistent with our research. There are studies showing that the expression level of TNF-α in patients with AS is a promising serological indicator involved in AS\(^21\). We then examined the bone changes before and after treatment in the two groups of patients and found that infliximab significantly improved bone erosion and tendon thickening compared with methotrexate, but had lirter effect on improving osteophytes and tendon calcification, indicating that infliximab significantly improved the bone quality of patients with AS with better treatment effect. According to previous research, infliximab is ineffective in 10% of patients, suggesting that lowering the dose may improve the efficacy\(^22\). In order to further confirm the clinical efficacy of infliximab in AS patients, we further analyzed the morning stiffness time, BASFI, BASDAI, and PGA scores of patients before and after treatment. The improvement of various indexes in INF group was significantly higher than that in MTX group after treatment, suggesting that infliximab remarkably improved the clinical symptoms of patients with AS. Studies by Vicente et al\(^23\) also verified that infliximab was a TNF-α inhibitor with high application frequency and considerable efficacy.

TNF-α and IL-33 are involved in the development of AS. According to the PGA score after treatment, we divided the patients into two groups: good curative effect group and poor curative effect group. It was found that the expression levels of serum TNF-α and IL-33 in the good curative effect group were significantly lower than those in the poor curative effect group, suggesting that TNF-α and IL-33 can sever as predictors of the curative effect of AS. Further plotting the ROC revealed that, the AUC of IL-33 in efficacy prediction of AS was 0.939, 95CI%: 0.886-0.992, the sensitivity was 93.33%, the specificity was 88.00%, and the Youden index was 81.33%. While the AUC of TNF-α in efficacy prediction of AS was 0.939, 95CI%: 0.886-0.992, the sensitivity was 93.33%, the specificity was 88.00%, and the Youden index was 81.33%. All these indicated that TNF-α and IL-33 had high predictive value in patients with AS.

The therapeutic effect of infliximab is widely acknowledged clinically, but the relapse rate after discontinuation is high, and the onset time is short, suggesting that patients with severe active AS must continue treatment\(^24\). Studies have shown that patients receiving long-term infliximab therapy still maintain stable body function and spinal activity\(^25\). The treatment time of this study is relatively conventional, but in order to further confirm the clinical efficacy of infliximab, we hope to change the treatment dose and continue to conduct in-depth research on its long-term efficacy to provide valuable references for clinical practice.

In summary, infliximab can significantly improve bone status and has positive effect in AS patients. TNF-α and IL-33 are expected to be used as predictive indicators of AS efficacy.

\[\text{Figure 3. ROC curve for predicting the efficacy of TNF-α and IL-33 in AS patients.}\]

The red line was the ROC curve of IL-33 in efficacy prediction of AS, and the AUC was 0.853, 95CI%: 0.754-0.952, sensitivity: 93.33%, specificity: 88.00%, and Youden index: 81.33%. The blue line was the ROC curve of TNF-α in efficacy prediction of AS, the AUC was 0.939, 95CI%: 0.886-0.992, the sensitivity was 93.33%, the specificity was 88.00%, and the Youden index was 81.33%.
Authors' contributions

LL wrote the manuscript, interpreted and analyzed the data. BC and GW designed the study and performed the experiment. HZ was responsible for the analysis and discussion of the data. All authors read and approved the final manuscript.

References

1. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377: 2127-2137.
2. Jang JH, Ward MM, Rucker AN, Reveille JD, Davis JC Jr, Weisman MH, Leach TJ. Ankylosing spondylitis: patterns of radiographic involvement—a re-examination of accepted principles in a cohort of 769 patients. Radiology 2011;258:192-198.
3. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650-657.
4. Akkoc N. Are spondyloarthopathies as common as rheumatoid arthritis worldwide? Curr Rheumatol Rep 2008;10:371-378.
5. Ho HH, Chen JY. Ankylosing spondylitis: Chinese perspective, clinical phenotypes, and associated extra-articular systemic features. Curr Rheumatol Rep 2013; 15:344.
6. Hsieh MY, Kuo CF. FRI0428 Epidemiology of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study. Ann Rheum Dis 2016;2016:590-591.
7. Li YH, Zhang XY, Li OH, Zheng DH, Dai L. Andersson lesion in ankylosing spondylitis:a clinical study of 14 cases. Zhonghua Yi Xue Za Zhi 2017;97:517-521.
8. Golder V, Schachna L. Ankylosing spondylitis: an update. Aust Fam Physician 2013;42:780-784.
9. Liu Z, Gao L, Wang P, Xie Z, Cen S, Li Y, Wu X, Wang L, Su H, Deng W, et al. TNF-α induced the enhanced apoptosis of mesenchymal stem cells in ankylosing spondylitis by overexpressing TRAIL-R2. Stem cells nt 2017; 2017: 4521324.
10. Li XL, Lin TT, Qi CY, Yuan L, Xia LP, Shen H, Lu J. Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor. J Investig Med 2013;61:848-851.
11. Elalouf O, Elkayam O. Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag 2015;11:1719.
12. Haroon NN, Srigantha J, Al Ghanim N, Inman RD, Cheung AM. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:155-161.
13. van der Linden S, Valkenburg HA, Cats A. Valkenburg, and Arnold Cats. “Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 1984; 27:361-368.
14. Mahmoudi M, Aslani S, Nicknam MH, Karami J, Jamshidi AR. New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications. Mod Rheumatol 2017;27:198-209.
15. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:1369-1374.
16. Maksymowych WP, Chiwchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
17. Han GW, Zeng LW, Liang CX, Cheng BL, Yu BS, Li HM, Zeng FF, Liu SY. Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol 2011;30:1583-1588.
18. Arends S, Spoorenberg A, Houtman PM, Leijms MA, Bos R, Kallenberg CG, Groen H, Brouwer E, van der Veer E. The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2012;14:R98.
19. Gibofsky A, Palmer W, Keystone E, et al. Safety profiles of disease-modifying anti-rheumatic drugs and biologics in patients with rheumatoid arthritis: observations from the RADIUS registry. Arthritis Rheum 2009;60:1593.
20. Gong SH, Shi XB, Bao CL. Expression and significance of IL-33 and IL-33 mRNA in peripheral blood of patients with ankylosing spondylitis. Chinese Journal of Primary Medicine and Pharmacy 2017;24:45-48.
21. Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imagingdata. Arthritis Rheum 2005;53:8568-63.
22. Moreno M, Gratacos J, Torrente-Segarra V, Sanmarti R, Morà R, Pontes C, Llop M, Juanola X. REMINEA study roup: Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Arthritis Res Ther 2019;21:88.
23. Escudero-Vilaplana V, Ramírez-Herráiz E, Alanón-Plaza E, Trovato-López N, García-Vicuña R, Carreño-Pérez L, Morell-Baladrón A, Sanjurjo-Sáez M. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice. Int J Clin Pharm 2015; 37: 808-814.
24. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-234.
25. Poddubnyy D, Fedorova A, Listing J, Haibel H, Baraliakos X, Braun J, Sieper J. Physical function and spinal mobility remain stable despite radiographic spinal progression in patients with ankylosing spondylitis treated with TNF-α inhibitors for up to 10 years. J Rheumatol 2016; 43:2142-2148.